Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Colorectal Cancer"
DOI: 10.1016/j.clcc.2016.09.007
Abstract: Background: For borderline resectable colorectal cancer liver metastases (CLM), systemic treatment can help to achieve R0 resection and reduce the risk of relapse. We assessed the role of perioperative triplet chemotherapy in combination with cetuximab… read more here.
Keywords: risk; ras wild; colorectal cancer; borderline resectable ... See more keywords
Phase II APEC trial: The impact of primary tumor side on outcomes of first‐line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild‐type metastatic colorectal cancer
Sign Up to like & getrecommendations! Published in 2019 at "Asia-Pacific Journal of Clinical Oncology"
DOI: 10.1111/ajco.13154
Abstract: The open‐label, nonrandomized, phase II APEC study enrolled 167 patients with RAS wild‐type (wt) metastatic colorectal cancer (mCRC) to investigate the safety and efficacy of first‐line, every‐2‐weeks cetuximab plus investigator's choice of FOLFIRI or FOLFOX… read more here.
Keywords: phase apec; metastatic colorectal; ras wild; type metastatic ... See more keywords
Next-Generation Sequencing of Circulating Tumor DNA Can Optimize Second-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer after Progression on anti-EGFR Therapy: Time to Rethink Our Approach
Sign Up to like & getrecommendations! Published in 2022 at "Oncology Research and Treatment"
DOI: 10.1159/000521845
Abstract: Background: Management of Ras wild-type colorectal cancer (CRC) patients upon disease progression after the successful use of targeted treatment with anti-EGFR monoclonal antibodies and backbone chemotherapy remains a clinical challenge. Summary: Development of treatment resistance… read more here.
Keywords: anti egfr; ras wild; treatment; tumor ... See more keywords
Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers
Sign Up to like & getrecommendations! Published in 2019 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/1758835919846421
Abstract: Background: Intensive triplet chemotherapy/bevacizumab significantly increased metastatic colorectal cancer (MCRC) outcome. This phase II study investigated the safety/activity of FIr-C/FOx-C triplet/cetuximab (CET) in first-line RAS wild-type and the prediction of individual limiting toxicity syndromes (LTS)… read more here.
Keywords: fir fox; ras wild; pharmacogenomic biomarkers; triplet ... See more keywords
A study of gene variation in All-RAS wild-type metastatic colorectal cancer and its correlation with cetuximab
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Gastrointestinal Oncology"
DOI: 10.21037/jgo-22-1237
Abstract: Background This study sought to explore the biological significance of genetic variation in RAS wild-type metastatic colorectal cancer (mCRC) in the real world, the difference in the efficacy of cetuximab in the treatment of mCRC… read more here.
Keywords: group; variation ras; ras wild; gene ... See more keywords
Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancer
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1160673
Abstract: Background The term “neo-RAS wild-type” refers to the switch to RAS wild-type disease in plasma circulating tumor DNA (ctDNA) from originally RAS mutant colorectal cancers. Consistently, the hypothesis to re-determine RAS mutational status in ctDNA… read more here.
Keywords: ras mutant; ctdna; neo ras; ras wild ... See more keywords
Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14246075
Abstract: Simple Summary Cell-free DNA RAS mutation is being increasingly monitored in metastatic colorectal cancer (mCRC) for disease molecular characterization and selecting eligible patients for anti-EGFR initiation and rechallenge. Here, we monitored a homogeneous mCRC RAS… read more here.
Keywords: cfdna ras; ras mutations; first line; ras wild ... See more keywords
Safety Assessment on Serious Adverse Events of Targeted Therapeutic Agents Prescribed for RAS Wild-Type Metastatic Colorectal Cancer: Systematic Review and Network Meta-Analysis
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Environmental Research and Public Health"
DOI: 10.3390/ijerph19159196
Abstract: Despite substantially elevated risk of serious adverse events (SAEs) from targeted therapy in combination with chemotherapy, comprehensive pharmacovigilance research is limited. This study aims to systematically assess SAE risks of commonly prescribed targeted agents (bevacizumab,… read more here.
Keywords: risk serious; risk; serious adverse; ras wild ... See more keywords
Diagnostic Limitation of Fine-Needle Aspiration (FNA) on Indeterminate Thyroid Nodules Can Be Partially Overcome by Preoperative Molecular Analysis: Assessment of RET/PTC1 Rearrangement in BRAF and RAS Wild-Type Routine Air-Dried FNA Specimens
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms18040806
Abstract: Molecular markers are helpful diagnostic tools, particularly for cytologically indeterminate thyroid nodules. Preoperative RET/PTC1 rearrangement analysis in BRAF and RAS wild-type indeterminate thyroid nodules would permit the formulation of an unambiguous surgical plan. Cycle threshold… read more here.
Keywords: ptc1 rearrangement; ras wild; ret ptc1; braf ras ... See more keywords
Comparison of UGT1A1 Polymorphism as Guidance of Irinotecan Dose Escalation in RAS Wild-Type Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab Plus FOLFIRI as the First-Line Therapy
Sign Up to like & getrecommendations! Published in 2022 at "Oncology Research"
DOI: 10.3727/096504022x16451187313084
Abstract: Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism plays a crucial role in the increased susceptibility and toxicity of patients to irinotecan. This retrospective, observational study compared the clinical outcomes and adverse events (AEs) in RAS wild-type… read more here.
Keywords: treated cetuximab; cetuximab bevacizumab; therapy; patients treated ... See more keywords